Pseudoprogression of Melanoma Brain Metastases

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2018 Nov 11

PMID 30413981

Citations 12

Authors

Jillian L Simard

Melanie Smith

Sunandana Chandra

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Immune checkpoint inhibitors are increasingly being used to treat melanoma brain metastases. One potential complication of immune checkpoint inhibitors is a phenomenon called pseudoprogression, in which a tumor transiently increases in size due to lymphocyte infiltration. This article reviews the characteristics of pseudoprogression and their clinical implications.

Recent Findings: Pseudoprogression can be challenging to differentiate from true progression noted clinically or radiographically, thereby complicating management decisions and potentially confusing patients and their families. The transient tumor enlargement can also cause symptoms that mimic true tumor progression. Because the use of immunotherapy on melanoma brain metastases is a relatively new treatment paradigm, there is limited evidence to guide clinical decision-making and prognostication related to pseudoprogression.

Citing Articles

A Case of a Large Brain Metastasis: Time for Multidisciplinary Consultation.

Guberinic A, Piet B, Meijer F, Gijtenbeek A, Laan M Cureus. 2024; 16(11):e74468.

PMID: 39726445 PMC: 11669917. DOI: 10.7759/cureus.74468.

Response Assessment in Brain Metastases Managed by Stereotactic Radiosurgery: A Reappraisal of the RANO-BM Criteria.

Douri K, Iorio-Morin C, Mercure-Cyr R, Figueiredo G, Touchette C, Masson-Cote L Curr Oncol. 2023; 30(11):9382-9391.

PMID: 37999099 PMC: 10670467. DOI: 10.3390/curroncol30110679.

Immunotherapy as a Turning Point in the Treatment of Melanoma Brain Metastases.

Fernandes G Discoveries (Craiova). 2023; 11(2):e169.

PMID: 37583899 PMC: 10425169. DOI: 10.15190/d.2023.8.

Incorporating lesion-to-lesion heterogeneity into early oncology decision making.

Kumar R, Qi T, Cao Y, Topp B Front Immunol. 2023; 14:1173546.

PMID: 37350966 PMC: 10282604. DOI: 10.3389/fimmu.2023.1173546.

Dosimetric and clinical analysis of pseudo-progression versus recurrence after hypo-fractionated radiotherapy for brain metastases.

Yang S, Ma Y, Xu Y, Liu Q, Zhang Y, Huang X Radiat Oncol. 2023; 18(1):30.

PMID: 36788610 PMC: 9930329. DOI: 10.1186/s13014-023-02214-7.

References

Guy Jr G, Thomas C, Thompson T, Watson M, Massetti G, Richardson L . Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR Morb Mortal Wkly Rep. 2015; 64(21):591-6. PMC: 4584771. View

Davies M, Liu P, McIntyre S, Kim K, Papadopoulos N, Hwu W . Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2010; 117(8):1687-96. DOI: 10.1002/cncr.25634. View

Kalkanis S, Kondziolka D, Gaspar L, Burri S, Asher A, Cobbs C . The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2009; 96(1):33-43. PMC: 2808516. DOI: 10.1007/s11060-009-0061-8. View

Welzel G, Fleckenstein K, Schaefer J, Hermann B, Kraus-Tiefenbacher U, Mai S . Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys. 2008; 72(5):1311-8. DOI: 10.1016/j.ijrobp.2008.03.009. View

Stokes W, Binder D, Jones B, Oweida A, Liu A, Rusthoven C . Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy. J Neuroimmunol. 2017; 313:118-122. DOI: 10.1016/j.jneuroim.2017.10.006. View

Skeie B, Skeie G, Enger P, Ganz J, Heggdal J, Ystevik B . Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. World Neurosurg. 2011; 75(5-6):684-91. DOI: 10.1016/j.wneu.2010.12.054. View

Wong E, Rowbottom L, Tsao M, Zhang L, McDonald R, Danjoux C . Correlating symptoms and their changes with survival in patients with brain metastases. Ann Palliat Med. 2016; 5(4):253-266. DOI: 10.21037/apm.2016.09.01. View

Long G, Trefzer U, Davies M, Kefford R, Ascierto P, Chapman P . Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13(11):1087-95. DOI: 10.1016/S1470-2045(12)70431-X. View

Westphal D, Glitza Oliva I, Niessner H . Molecular insights into melanoma brain metastases. Cancer. 2017; 123(S11):2163-2175. DOI: 10.1002/cncr.30594. View

10.

Sinha R, Sage W, Watts C . The evolving clinical management of cerebral metastases. Eur J Surg Oncol. 2016; 43(7):1173-1185. DOI: 10.1016/j.ejso.2016.10.006. View

11.

Chang E, Wefel J, Hess K, Allen P, Lang F, Kornguth D . Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10(11):1037-44. DOI: 10.1016/S1470-2045(09)70263-3. View

12.

Wolchok J, Hoos A, ODay S, Weber J, Hamid O, Lebbe C . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624. View

13.

Cohen J, Alomari A, Vortmeyer A, Jilaveanu L, Goldberg S, Mahajan A . Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunol Res. 2015; 4(3):179-82. PMC: 4881844. DOI: 10.1158/2326-6066.CIR-15-0160. View

14.

Lin N, Wefel J, Lee E, Schiff D, van den Bent M, Soffietti R . Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013; 14(10):e407-16. DOI: 10.1016/S1470-2045(13)70308-5. View

15.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

16.

Kiess A, Wolchok J, Barker C, Postow M, Tabar V, Huse J . Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015; 92(2):368-75. PMC: 4955924. DOI: 10.1016/j.ijrobp.2015.01.004. View

17.

Lin N, Lee E, Aoyama H, Barani I, Barboriak D, Baumert B . Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015; 16(6):e270-8. DOI: 10.1016/S1470-2045(15)70057-4. View

18.

Goldberg S, Gettinger S, Mahajan A, Chiang A, Herbst R, Sznol M . Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016; 17(7):976-983. PMC: 5526047. DOI: 10.1016/S1470-2045(16)30053-5. View

19.

Margolin K, Ernstoff M, Hamid O, Lawrence D, McDermott D, Puzanov I . Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13(5):459-65. DOI: 10.1016/S1470-2045(12)70090-6. View

20.

Retsas S, Gershuny A . Central nervous system involvement in malignant melanoma. Cancer. 1988; 61(9):1926-34. DOI: 10.1002/1097-0142(19880501)61:9<1926::aid-cncr2820610934>3.0.co;2-i. View